Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.
Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.
ImClone Protocol Generates More Questions Than Answers.
Phase III Trial Would Give Clearer Picture Of C225 Role.
Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.
Levine Leaves Presidency Of Rockefeller University.
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer - Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science
- The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion
